RBC Says Verastem Interim Analysis In Ovarian Cancer Reinforces Enthusiasm

  • With the anticipation of a 2Q program update, Verastem Oncology VSTM announced that its interim analysis findings for the RAMP 201 program for recurrent low-grade serous ovarian cancer (LGSOC) continue evaluation in both monotherapy and combination regimens. 
  • With incremental updates from ASCO, reiterated KOL enthusiasm, and more updates are upcoming in 2022 on a longer runway, RBC Capital continues to like the VSTM setup.
  • The company plans to complete enrollment of all four trial cohorts in the second half of this year.
  • Related: Truist Sees 350% Upside On This Cancer-Focused Biopharma Stock - Read Why.
  • It has reiterated the Outperform, Speculative Risk rating, and a price target of $5.
  • RBC Capitals believes VSTM has exhibited differentiating safety profile exhibited thus far, all of which it finds reassuring.
  • The analysts noted that around 6% had discontinued the trial based on treatment-related adverse events compared to ~30% for tyrosine kinase inhibitors' current standard of care.
  • However, the update has generated interest in the clarity around the planned regulatory interactions, which are still pending and will guide go-forward dosing and trial design. 
  • Price Action: VSTM shares are up 6.15% at $1.30 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: Analyst ColorBiotechNewsPenny StocksHealth CareAnalyst RatingsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!